Cargando…

Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil

BACKGROUND AND OBJECTIVES: Malignant hyperthermia is an autosomal dominant hypermetabolic pharmacogenetic syndrome, with a mortality rate of 10%–20%, which is triggered by the use of halogenated inhaled anesthetics or muscle relaxant succinylcholine. The gold standard for suspected susceptibility to...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Helga Cristina Almeida da, Ferreira, Gisele, Rodrigues, Gislene, Santos, Joilson Moura dos, Andrade, Pamela Vieira, Hortense, Alexandre, Perez, Marcelo Vaz, Amaral, José Luiz Gomes do
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391845/
https://www.ncbi.nlm.nih.gov/pubmed/30935497
http://dx.doi.org/10.1016/j.bjane.2018.09.009
_version_ 1784770941831610368
author Silva, Helga Cristina Almeida da
Ferreira, Gisele
Rodrigues, Gislene
Santos, Joilson Moura dos
Andrade, Pamela Vieira
Hortense, Alexandre
Perez, Marcelo Vaz
Amaral, José Luiz Gomes do
author_facet Silva, Helga Cristina Almeida da
Ferreira, Gisele
Rodrigues, Gislene
Santos, Joilson Moura dos
Andrade, Pamela Vieira
Hortense, Alexandre
Perez, Marcelo Vaz
Amaral, José Luiz Gomes do
author_sort Silva, Helga Cristina Almeida da
collection PubMed
description BACKGROUND AND OBJECTIVES: Malignant hyperthermia is an autosomal dominant hypermetabolic pharmacogenetic syndrome, with a mortality rate of 10%–20%, which is triggered by the use of halogenated inhaled anesthetics or muscle relaxant succinylcholine. The gold standard for suspected susceptibility to malignant hyperthermia is the in vitro muscle contracture test in response to halothane and caffeine. The determination of susceptibility in suspected families allows the planning of safe anesthesia without triggering agents for patients with known susceptibility to malignant hyperthermia by positive in vitro muscle contracture test. Moreover, the patient whose suspicion of malignant hyperthermia was excluded by the in vitro negative muscle contracture test may undergo standard anesthesia. Susceptibility to malignant hyperthermia has a variable manifestation ranging from an asymptomatic subject presenting a crisis of malignant hyperthermia during anesthesia with triggering agents to a patient with atrophy and muscle weakness due to central core myopathy. The aim of this study is to analyze the profile of reports of susceptibility to malignant hyperthermia confirmed with in vitro muscle contracture test. METHOD: Analysis of the medical records of patients with personal/family suspicion of malignant hyperthermia investigated with in vitro muscle contracture test, after given written informed consent, between 1997 and 2010. RESULTS: Of the 50 events that motivated the suspicion of malignant hyperthermia and family investigation (sample aged 27 ± 18 years, 52% men, 76% white), 64% were investigated for an anesthetic malignant hyperthermia crisis, with mortality rate of 25%. The most common signs of a malignant hyperthermia crisis were hyperthermia, tachycardia, and muscle stiffness. Susceptibility to malignant hyperthermia was confirmed in 79.4% of the 92 relatives investigated with the in vitro muscle contracture test. CONCLUSION: The crises of malignant hyperthermia resembled those described in other countries, but with frequency lower than that estimated in the country.
format Online
Article
Text
id pubmed-9391845
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93918452022-08-21 Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil Silva, Helga Cristina Almeida da Ferreira, Gisele Rodrigues, Gislene Santos, Joilson Moura dos Andrade, Pamela Vieira Hortense, Alexandre Perez, Marcelo Vaz Amaral, José Luiz Gomes do Braz J Anesthesiol Scientific Article BACKGROUND AND OBJECTIVES: Malignant hyperthermia is an autosomal dominant hypermetabolic pharmacogenetic syndrome, with a mortality rate of 10%–20%, which is triggered by the use of halogenated inhaled anesthetics or muscle relaxant succinylcholine. The gold standard for suspected susceptibility to malignant hyperthermia is the in vitro muscle contracture test in response to halothane and caffeine. The determination of susceptibility in suspected families allows the planning of safe anesthesia without triggering agents for patients with known susceptibility to malignant hyperthermia by positive in vitro muscle contracture test. Moreover, the patient whose suspicion of malignant hyperthermia was excluded by the in vitro negative muscle contracture test may undergo standard anesthesia. Susceptibility to malignant hyperthermia has a variable manifestation ranging from an asymptomatic subject presenting a crisis of malignant hyperthermia during anesthesia with triggering agents to a patient with atrophy and muscle weakness due to central core myopathy. The aim of this study is to analyze the profile of reports of susceptibility to malignant hyperthermia confirmed with in vitro muscle contracture test. METHOD: Analysis of the medical records of patients with personal/family suspicion of malignant hyperthermia investigated with in vitro muscle contracture test, after given written informed consent, between 1997 and 2010. RESULTS: Of the 50 events that motivated the suspicion of malignant hyperthermia and family investigation (sample aged 27 ± 18 years, 52% men, 76% white), 64% were investigated for an anesthetic malignant hyperthermia crisis, with mortality rate of 25%. The most common signs of a malignant hyperthermia crisis were hyperthermia, tachycardia, and muscle stiffness. Susceptibility to malignant hyperthermia was confirmed in 79.4% of the 92 relatives investigated with the in vitro muscle contracture test. CONCLUSION: The crises of malignant hyperthermia resembled those described in other countries, but with frequency lower than that estimated in the country. Elsevier 2019-01-14 /pmc/articles/PMC9391845/ /pubmed/30935497 http://dx.doi.org/10.1016/j.bjane.2018.09.009 Text en © 2018 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Silva, Helga Cristina Almeida da
Ferreira, Gisele
Rodrigues, Gislene
Santos, Joilson Moura dos
Andrade, Pamela Vieira
Hortense, Alexandre
Perez, Marcelo Vaz
Amaral, José Luiz Gomes do
Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil
title Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil
title_full Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil
title_fullStr Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil
title_full_unstemmed Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil
title_short Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil
title_sort profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in brazil
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391845/
https://www.ncbi.nlm.nih.gov/pubmed/30935497
http://dx.doi.org/10.1016/j.bjane.2018.09.009
work_keys_str_mv AT silvahelgacristinaalmeidada profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil
AT ferreiragisele profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil
AT rodriguesgislene profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil
AT santosjoilsonmourados profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil
AT andradepamelavieira profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil
AT hortensealexandre profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil
AT perezmarcelovaz profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil
AT amaraljoseluizgomesdo profileofmalignanthyperthermiasusceptibilityreportsconfirmedwithmuscularcontracturetestinbrazil